Human chitotriosidase: A sensitive biomarker of sarcoidosis

Journal of Clinical Immunology

Volumn 33, Issue 1, 2013, Pages 264-270

  Bargagli, Elena ^a   Bennett, David ^a   Maggiorelli, Claudia ^a   Di Sipio, Pasquale ^a   Margollicci, Maria ^b   Bianchi, Nicola ^b   Rottoli, Paola ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Chitotriosidase; Sarcoidosis; Serum biomarker

Indexed keywords

CHITOTRIOSIDASE; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ARTICLE; CD4 CD8 RATIO; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME SPECIFICITY; FEMALE; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL; REMISSION; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; AGED; BLOOD; ENZYMOLOGY; FOLLOW UP; IMMUNOLOGY; METABOLISM; PROGNOSIS; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEXOSAMINIDASES; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876443196     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9754-4     Document Type: Article

References (38)

1. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:149-73.
2. Yamamoto M, Sharma OP, Hosoda Y. Special report: the 1991 descriptive definition of sarcoidosis. Sardoidosis. 1992;9:33-4.
3. Agostini C, Trentin L, Facco M, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol. 1996;157:910-8.
4. Agostini C, Semenzato G. Cytokines in sarcoidosis. Semin Respir Infect. 1998;13:184-96.
5. Prior C, Knight RA, Herold M. Pulmonary sarcoidosis: patterns of cytokine release in vitro. Eur Respir J. 1996;9:47-53.
6. Gurrieri C, Bortoli M, Brunetta E, et al. Cytokines, chemokines and other biomolecular markers in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22 Suppl 1:S9-S14.
7. Baudin B. ACE for sarcoidosis diagnosis. Pathol Biol. 2005;53:183-8.
8. Lynch JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med. 1997;18:755-85.
9. Judson MA, Baughman RP, Thompson BW, et al. Two years prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:204-11.
10. Corte TJ, Wells AU, Nicholson AG, et al. Pulmonary hypertension in sarcoidosis: a review. Respirology. 2011;16:69-77.
11. Ziegenhagen MW, Rothe ME, Schlaak M, et al. BAL and sierological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21:407-13.
12. Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med. 1994;149:893-8.
13. Wasfi YS, Rose CS. A new tool to assess sarcoidosis severity. Chest. 2006;129:1234-45.
14. Prasse A, Katic C, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med. 2008;177:330-6.
15. Baughman RP, Nagai S, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:56-64.
16. Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum and exhaled gas. Clin Chest Med. 2008;29:445-58.
17. Scadding JG. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years' observation. BMJ. 1961;2:1165-72.
18. Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273:25680-5.
19. Michelakakis H, Dimitriou E, Labadaridis I. The expanding spectrum of disorders with elevated plasma chitotriosidase activity: an update. J Inherit Metab Dis. 2004;27:705-6.
20. Altarescu G, Rudensky B, Abrahamov A, et al. Plasma chitotriosidase activity in patients with beta-thalassemia. Am J Hematol. 2003;72:285-6.
21. Barone R, Simpore J, Malaguarnera L, et al. Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. Clin Chim Acta. 2003;331:79-85.
22. Rottoli P, Magi B, Perari MG, et al. Cytokine profile and proteome analysis in BAL of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics. 2005;5:1423-30.
23. Aguilera B, Ghauharali-Van der Vlugt K, Helmond MT, et al. Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem. 2003;278:40911-6.
24. Grosso S, Margollicci MA, Bargagli E, et al. Serum levels of chitotriosidase as a marker of disease activity and clinical stage in sarcoidosis. Scand J Clin Lab Invest. 2004;64:57-62.
25. Bargagli E, Margollicci MA, Perrone A, et al. Chitotriosidase analysis in bronchoalveolar lavage of patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24:59-64.
26. Rothkranz-Kos S, van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of infiammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem. 2003;49:1510-7.
27. Bargagli E, Margollicci M, Luddi A, et al. Chitotriosidase activity in patients with interstitial lung diseases. Resp Med. 2007;101:2176-81.
28. Bargagli E, Margollicci M, Nikiforakis N, et al. Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis. Respiration. 2007;74(5):548-52.
29. Tercelj W, Salobir B, Siwcic S, et al. Chitotriosidase activity in sarcoidosis and some other pulmonary diseases. Scand J Clin Lab Invest. 2009;69:575-8.
30. Brunner J, Scholl-Burgi S, Zimmerhackl LB. Chitotriosidase as a marker of disease activity in sarcoidosis. Rheumatol Int. 2007;27:1171-2.
31. Newman LS, Rose CS, Bresnitz EA, and the ACCESS Research Group. A case-control etiological study of sarcoidosisenvironmental and occupational risk factors. Am J Crit Care Med. 2004;170:1324-30.
32. Tercelj M, Stopincek S, Salobir B, et al. In vitro and in vivo reactivity to fungal cell wall agents in sarcoidosis. Clin Exp Immunol. 2011;166:87-93.
33. Tercelj M, Salobir B, Zupancic M, Rylander R. Antifungal medication is efficient in the treatment of sarcoidosis. Ther Adv Respir Dis. 2011;5(3):157-62.
34. Tercelj M, Rott T, Rylander R. Antifungal treatment in sarcoidosisa pilot intervention trial. Resp Med. 2007;101:774-8.
35. Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010;137:1391-7.
36. Tzouvelekis A, Kouliatsis G, Anevlavis S, et al. Serum biomarkers in interstitial lung diseases. Respir Res. 2005;6:78.
37. Hunninghake GW, Bedell GN, Zavala DC, et al. Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis. Am Rev Respir Dis. 1983;128:634-8.
38. Prior C, Barbee RA, Evans PM, et al. Lavage versus serum measurements of lysozyme, angiotensin converting enzyme and other inflammatory markers in pulmonary sarcoidosis. Eur Respir J. 1990;3:1146-54.